A- A A+

Dextroamphetamine-Amphetamine.

Sharbaf Shoar N, Molla M.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 May 18.

https://www.ncbi.nlm.nih.gov/books/NBK507808/

Are Ecstasy Induced Serotonergic Alterations Overestimated For The Majority Of Users? 

Balázs Szigeti, Adam R Winstock, David Erritzoe, and Larissa J Maier 

Journal of Psychopharmacology, First Published May 7, 2018, doi.org/10.1177/0269881118767646

http://journals.sagepub.com/doi/full/10.1177/0269881118767646

USA. Meth, the Forgotten Killer, Is Back. And It’s Everywhere.

PORTLAND, Ore. — They huddled against the biting wind, pacing from one corner to another hoping to score heroin or pills. But a different drug was far more likely to be on offer outside the train station downtown, where homeless drug users live in tents pitched on the sidewalk.

“Everybody has meth around here — everybody,” said Sean, a 27-year-old heroin user who hangs out downtown and gave only his first name. “It’s the easiest to find.”

The scourge of crystal meth, with its exploding labs and ruinous effect on teeth and skin, has been all but forgotten amid national concern over the opioid crisis. But 12 years after Congress took aggressive action to curtail it, meth has returned with a vengeance. Here in Oregon, meth-related deaths vastly outnumber those from heroin. At the United States border, agents are seizing 10 to 20 times the amounts they did a decade ago. Methamphetamine, experts say, has never been purer, cheaper or more lethal. (New York Times, 13.02.2018)

https://www.nytimes.com/2018/02/13/us/meth-crystal-drug.html

MDMA Safer Use Guide

How much MDMA should I take? How should I consume it? Should I snort MDMA? How long does MDMA take to kick in? Can I mix MDMA with alcohol or cocaine? How much water should I drink while on MDMA? What risks are there with using MDMA? How often is too often to use MDMA?

There are no definitive answers to these questions, but this graphic highlights some good things to consider when using MDMA. (Talking Drugs, UK, 2018)

https://www.talkingdrugs.org/safer-drug-use-guides/mdma1

Konsum von neuen psychoaktiven Substanzen und Methamphetamin - Auswertung der Daten aus 6 deutschen Bundesländern

The consumption of new psychoactive substances and methamphetamine—analysis of data from 6 German federal states

Dtsch Arztebl Int 2018; 115(4): 49-55; DOI: 10.3238/arztebl.2018.0049

Gomes de Matos, Elena; Hannemann, Tessa-Virginia; Atzendorf, Josefine; Kraus, Ludwig; Piontek, Daniela

https://www.aerzteblatt.de/archiv/195858/Konsum-von-neuen-psychoaktiven-Substanzen-und-Methamphetamin

Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy.

Wagner MT, Mithoefer MC, Mithoefer AT, MacAulay RK, Jerome L, Yazar-Klosinski B, Doblin R.

J Psychopharmacol. 2017 Aug;31(8):967-974. doi: 10.1177/0269881117711712.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544120/

Misplaced Ecstasy? Questioning the Role of Psychedelics as Therapy

(Medscape, 26.10.2017)

https://www.medscape.com/viewarticle/887354

PTBS: Ecstasy erleichtert Verarbeitung traumatischer Erlebnisse

Santa Cruz/Kalifornien – Die Behandlung mit MDMA, besser bekannt als die Mode­droge der 1980er-Jahre Ecstasy, hat in einer kleinen randomisierten Doppelblindstudie die Symptome einer posttraumatischen Belastungsstörung (PTBS) gelindert. Die in Lancet Psychiatry(2018; doi: 10.1016/S2215-0366(18)30135-4) veröffentlichten Ergebnisse sollen jetzt in einer Phase-3-Studie überprüft werden, zu der die US-Arzneimittelbehörde FDA bereits ihren Segen gegeben hat. Mit einer Zulassungwird allerdings frühestens 2021 gerechnet. (aerzteblatt.de, 02.05.2018)

https://www.aerzteblatt.de/nachrichten/94873/PTBS-Ecstasy-erleichtert-Verarbeitung-traumatischer-Erlebnisse

Defending MDMA as a Treatment for PTSD

(Medscape, 11.12.2017)

https://www.medscape.com/viewarticle/889639

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial

Mithoefer, Michael C et al.

The Lancet Psychiatry , Volume 0 , Issue 0 , Published 01 May 2018, doi.org/10.1016/S2215-0366(18)30135-4

https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(18)30135-4/abstract

Australien. Cracks in the Ice smartphone app provides more Australians with information about crystal methamphetamine (ice)

A smartphone app developed by researchers from the National Drug and Alcohol Research Centre (NDARC) at UNSW and National Drug Research Institute (NDRI) at Curtin University will allow more Australians to access trusted, evidence-based information and resources about crystal methamphetamine (ice). (NDARC/UNSW, 09.01.2018)

https://ndarc.med.unsw.edu.au/news/cracks-ice-smartphone-app-provides-more-australians-information-about-crystal-methamphetamine

Methamphetamine-type stimulant use in Lao PDR: qualitative findings from users aged 15–25 years in Vientiane Capital and Vientiane Province

Vanphanom Sychareun, Bangone Santavasy, Niramonh Chanlivong, Andrea Fischer, Nicholas Thomson, Robert Power and Jo Durham

Harm Reduction Journal2018, 15:17, doi.org/10.1186/s12954-018-0222-1

https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-018-0222-1

Treatment of methamphetamine addicts in the clinical practice in Germany

Katharina Schoett, Lisbon Addictions 2017, Second European Conference on Addictive Behaviours and Dependencies, Lissabon, 24.-26.10.2017

http://www.emcdda.europa.eu/system/files/attachments/7582/14H30_4_Katharina Schoett.pptx

Potential Psychiatric Uses for MDMA.

Yazar-Klosinski, B. and Mithoefer, M. (2017),

Clin. Pharmacol. Ther., 101: 194-196. doi:10.1002/cpt.565

https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.565

Social cognition and interaction in chronic users of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy").

Wunderli MD, Vonmoos M, Treichler L, Zeller C, Dziobek I, Kraemer T, Baumgartner MR, Seifritz E, Quednow BB.

Int J Neuropsychopharmacol. 2017 Oct 26. doi: 10.1093/ijnp/pyx098.

https://academic.oup.com/ijnp/advance-article/doi/10.1093/ijnp/pyx098/4565842

Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial.

Schottenfeld RS, Chawarski MC, Sofuoglu M, Chooi WT, Zaharim NM, M Yasin MA, Ahmad I, Syed Jaapar SZ, Vicknasingam BK.

Drug Alcohol Depend. 2018 Mar 10;186:130-137. doi: 10.1016/j.drugalcdep.2018.01.017.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29573648

Leidet die Empathiefähigkeit bei häufigem Ecstasykonsum?

Ecstasy kann das Bedürfnis verstärken, anderen Menschen nahe zu sein. Doch wie wirkt sich häufiger Ecstasy-Konsum langfristig auf die Empathiefähigkeit aus? Eine Studie aus der Schweiz hat Ecstasykonsumierende hierzu gründlich durchgecheckt. (drugcom.de, 24.11.2017)

https://www.drugcom.de/?id=aktuelles&idx=1141

mCPP: an undesired addition to the ecstasy market

MG BossongTM BruntJP Van DijkSM RigterJ. HoekHMJ GoldschmidtRJM Niesink

Journal of Psychopharmacology, Vol 24, Issue 9, pp. 1395 – 1401, doi.org/10.1177/0269881109102541

http://journals.sagepub.com/doi/abs/10.1177/0269881109102541

After 16 years of preliminary clinical trials, the Food and Drug Administration (FDA) in late August gave expedited approval for multiple phase 3 trials of 3,4-methylenedioxymethamphetamine (MDMA) as a potential “breakthrough therapy” for treatment of posttraumatic stress disorder (PTSD). (American Psychiatric Association, 20.10.2017)

http://psychnews.psychiatryonline.org/doi/full/10.1176/appi.pn.2017.pp10b6

The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Faraone SV.

Neurosci Biobehav Rev. 2018 Feb 8;87:255-270. doi: 10.1016/j.neubiorev.2018.02.001.

https://www.sciencedirect.com/science/article/pii/S0149763417308072?via%3Dihub

One of the main targets in the war on drugs could well become a drug to treat the scars of war. The U.S. Food and Drug Administration (FDA) has designated 3,4-methylenedioxymethamphetamine (MDMA), better known as the illegal drug ecstasy, a "breakthrough therapy" for posttraumatic stress disorder (PTSD), a status that may lead to faster approval.

The agency has also approved the design for two phase III studies of MDMA for PTSD that would be funded by the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit in Santa Cruz, California. MAPS announced the "breakthrough therapy" designation, made by FDA on 16 August, on its website today; if the group can find the money for the trials, which together could cost an estimated $25 million, they may start next spring and finish by 2021. (Science, 26.08.2017)

http://www.sciencemag.org/news/2017/08/all-clear-decisive-trial-ecstasy-ptsd-patients

Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies.

Kuypers KP, Dolder PC, Ramaekers JG, Liechti ME.

J Psychopharmacol. 2017 May;31(5):589-598. doi: 10.1177/0269881117699617.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418931/

Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder.

Najib J, Wimer D, Zeng J, Lam KW, Romanyak N, Paige Morgan E, Thadavila A.

J Cent Nerv Syst Dis. 2017 Aug 23;9:1179573517728090. doi: 10.1177/1179573517728090.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571766/

Methamphetamine dependence in methadone treatment services in Iran: the first literature review of a new health concern.

Alammehrjerdi Z, Ezard N, Dolan K.

Asian J Psychiatr. 2018 Jan 6;31:49-55. doi: 10.1016/j.ajp.2018.01.001.

Abstract

https://www.ncbi.nlm.nih.gov/pubmed/29414387

Breakthrough Therapy Designation ensures that FDA will work closely with MAPS to complete Phase 3 trials as efficiently as possible

MAPS and FDA have also reached agreement on design, primary endpoint, and statistical approach for Phase 3 trials

Posttraumatic stress disorder (PTSD) is a serious and life-threatening psychiatric condition with unmet medical need despite available treatments

MAPS is sponsoring two Phase 3 clinical trials of MDMA-assisted psychotherapy in patients with severe PTSD starting in 2018

MAPS, a non-profit research organization, has raised or pledged half of the $25 million estimated cost of these trials, with $12.5 million still needed. (MAPS - Multidisciplinary Association for Psychedelic Studies, 26.08.2017)

http://www.maps.org/news/media/6786-press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd,-agrees-on-special-protocol-assessment-for-phase-3-trials

Opioids and methamphetamine: a tale of two crises

The Lancet , Volume 391 , Issue 10122 , 713

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30319-2/fulltext